Abstract: A board with preformed seals. In an exemplary embodiment, a sealing material is applied to at least one edge of a board to form a preformed seal on that edge. The board is configured such that when the board is attached to a frame adjacent to a another board, at least a portion of the sealing material applied to the edge of the board seals against at least a portion of an edge another board. In one exemplary embodiment, the boards are configured to seal against edges of substantially identical boards. A plurality of the sheathing boards may be installed on a building frame to form a sheathing system that provides a moisture and/or gas barrier between and interior and exterior of a building.

Abstract: A board with preformed seals. In an exemplary embodiment, a sealing material is applied to at least one edge of a board to form a preformed seal on that edge. The board is configured such that when the board is attached to a frame adjacent to a another board, at least a portion of the sealing material applied to the edge of the board seals against at least a portion of an edge another board. In one exemplary embodiment, the boards are configured to seal against edges of substantially identical boards. A plurality of the sheathing boards may be installed on a building frame to form a sheathing system that provides a moisture and/or gas barrier between and interior and exterior of a building.

Abstract: A board with preformed seals. In an exemplary embodiment, a sealing material is applied to at least one edge of a board to form a preformed seal on that edge. The board is configured such that when the board is attached to a frame adjacent to a another board, at least a portion of the sealing material applied to the edge of the board seals against at least a portion of an edge another board. In one exemplary embodiment, the boards are configured to seal against edges of substantially identical boards. A plurality of the sheathing boards may be installed on a building frame to form a sheathing system that provides a moisture and/or gas barrier between and interior and exterior of a building.

Abstract: There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable Haemophilus influenzae (NTHi) vaccine. The vaccine is typically an oral whole killed NTHi vaccine.

Abstract: A board with preformed seals. In an exemplary embodiment, a sealing material is applied to at least one edge of a board to form a preformed seal on that edge. The board is configured such that when the board is attached to a frame adjacent to a another board, at least a portion of the sealing material applied to the edge of the board seals against at least a portion of an edge another board. In one exemplary embodiment, the boards are configured to seal against edges of substantially identical boards. A plurality of the sheathing boards may be installed on a building frame to form a sheathing system that provides a moisture and/or gas barrier between and interior and exterior of a building.

Abstract: A board with preformed seals. In an exemplary embodiment, a sealing material is applied to at least one edge of a board to form a preformed seal on that edge. The board is configured such that when the board is attached to a frame adjacent to a another board, at least a portion of the sealing material applied to the edge of the board seals against at least a portion of an edge another board. In one exemplary embodiment, the boards are configured to seal against edges of substantially identical boards. A plurality of the sheathing boards may be installed on a building frame to form a sheathing system that provides a moisture and/or gas barrier between and interior and exterior of a building.

Abstract: A board with preformed seals. In an exemplary embodiment, a sealing material is applied to at least one edge of a board to form a preformed seal on that edge. The board is configured such that when the board is attached to a frame adjacent to a another board, at least a portion of the sealing material applied to the edge of the board seals against at least a portion of an edge another board. In one exemplary embodiment, the boards are configured to seal against edges of substantially identical boards. A plurality of the sheathing boards may be installed on a building frame to form a sheathing system that provides a moisture and/or gas barrier between and interior and exterior of a building.

Abstract: There is described a method for selecting microbial isolates for use in oral killed vaccines against abnormal microbial colonization of mucosal surfaces by the microbes. The method comprises evaluating capacity of a plurality of different isolates of a microbe to activate antigen responsive cells to provide activation data for each microbial isolate, and the effectiveness of the isolates in reducing infection of a mucosal surface by the microbe to provide clearance data for each microbial isolate. An isolate, the activation data and clearance data for which correlate and is optimal for generating mucosal immunity against the microbe compared to the, or each, other of the isolates, or an isolate the activation data for which is optimal and a further isolate the clearance data for which is optimal, compared to the, or each, other of the isolates, respectively, is then selected for use in the vaccine.

Abstract: There is provided a method for prophylaxis or treatment of asthma in an individual. The method comprises administering to the individual an effective amount of a Non-typable Haemophilus influenzae (NTHi) vaccine. The vaccine is typically an oral whole killed NTHi vaccine.

Abstract: The present invention relates to novel oral compositions and vaccines, and in particular to oral vaccines for the prevention or therapy of candidiasis.

Abstract: There is described a method for selecting microbial isolates for use in oral killed vaccines against abnormal microbial colonisation of mucosal surfaces by the microbes. The method comprises evaluating capacity of a plurality of different isolates of a microbe to activate antigen responsive cells to provide activation data for each microbial isolate, and the effectiveness of the isolates in reducing infection of a mucosal surface by the microbe to provide clearance data for each microbial isolate. An isolate, the activation data and clearance data for which correlate and is optimal for generating mucosal immunity against the microbe compared to the, or each, other of the isolates, or an isolate the activation data for which is optimal and a further isolate the clearance data for which is optimal, compared to the, or each, other of the isolates, respectively, is then selected for use in the vaccine.

Abstract: The present invention relates to methods for determining predisposition to acute life threatening episodes (ALTE) and/or sudden infant death syndrome (SIDS) and, in particular, to methods of assessing potential susceptibility to development of ALTE and/or SIDS by determining a subject's total IgA and/or IgA1.

Abstract: There is disclosed a method for determining an administration regimen for an oral killed vaccine for use in immunising individuals in a population against an infection or disease. The method comprise administering the oral killed vaccine to one or more individuals in a population and identifying an indicative dosaging level of the vaccine which induces a reduction in immune system responsiveness to the vaccine in the one or more individuals. A further dosaging level that elicits an immune response in one or more individuals of the population without inducing the reduction in immune system responsiveness to the vaccine is then determined.

Abstract: A method of managing cache partitions provides a first pointer for higher priority writes and a second pointer for lower priority writes, and uses the first pointer to delimit the lower priority writes. For example, locked writes have greater priority than unlocked writes, and a first pointer may be used for locked writes, and a second pointer may be used for unlocked writes. The first pointer is advanced responsive to making locked writes, and its advancement thus defines a locked region and an unlocked region. The second pointer is advanced responsive to making unlocked writes. The second pointer also is advanced (or retreated) as needed to prevent it from pointing to locations already traversed by the first pointer. Thus, the pointer delimits the unlocked region and allows the locked region to grow at the expense of the unlocked region.

Abstract: The present invention relates to methods of predicting the risk of developing cancer and in particular to a method for diagnosing, and/or predicting the risk of developing gastric cancer in a subject infected with Helicobacter.

Abstract: The present invention relates to methods of identifying potentially therapeutic compounds for the treatment of hepatic disorders, preferably alcohol-induced hepatitis. Further, use of mammals in such methods, therapeutic compounds identified using said methods and the use of a Chinese Herb, CH-100, in the treatment of hepatic disorders, particularly alcohol-induced hepatic disorders, are described.

Abstract: The present invention relates to methods of identifying potentially therapeutic compounds for the treatment of hepatic disorders, preferably alcohol-induced hepatitis. Further, use of mammals in such methods, therapeutic compounds identified using said methods and the use of a Chinese Herb, CH-100, in the treatment of hepatic disorders, particularly alcohol-induced hepatic disorders, are described.

Abstract: A novel antigen from P. aeruginosa is provided. The use of the antigen in detecting/diagnosing P. aeruginosa as well as its use in eliciting an immune response are also provided.

Abstract: The present invention relates to methods for diagnosis, prevention and treatment of cardiovascular disorders or associated disorders and, in particular, to the use in such methods of regulating cytokine levels or activity. Compositions and kits suitable for use in the methods are described.

Abstract: The present invention relates to novel oral compositions and vaccines, and in particular to oral vaccines for the prevention or therapy of candidiasis.